Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 3×
“The percentage of patients with primary resistance in published phase III studies with CYP17A1 inhibitors (abiraterone [4,6] and orteronel [27,28]) and AR inhibitors (enzalutamide [5,7]), defined as the probability of radiographic progression within the first 3 months, are reported”
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · cited 1×
“The percentage of patients with primary resistance in published phase III studies with CYP17A1 inhibitors (abiraterone [4,6] and orteronel [27,28]) and AR inhibitors (enzalutamide [5,7]), defined as the probability of radiographic progression within the first 3 months, are reported”
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 2×
“In the 1990s dedicated studies on AR in CRPC revealed escape mechanisms from androgen blockade through either mutation or amplification of AR [14].”
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369 · cited 1×
“The percentage of patients with primary resistance in published phase III studies with CYP17A1 inhibitors (abiraterone [4,6] and orteronel [27,28]) and AR inhibitors (enzalutamide [5,7]), defined as the probability of radiographic progression within the first 3 months, are reported”
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747 · cited 2×
“PC cells can synthesize androgens through two mechanisms: the first through conversion from androgen precursors derived from adrenal glands such as androstenedione, DHEA and DHEA-S [22] and the second way is represented from the de novo synthesis from cholesterol [23].”
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675 · cited 1×
“Recently it has been shown that, in castration resistant PC (CRPC) patients, even small concentrations of extra-gonadal androgens persisting despite ADT could activate the AR pathway and that PC cells could synthesize their own androgens [3].”
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0968 · Cited by 229 · cited 8×
“AR binding with testosterone and DHT results in a conformational change of AR leading to a tight homodimeric binding to AREs.”
InfluentialNguyen, H. G., Yang, J. C., Kung, H.-J., Shi, X.-B., Tilki, D., Lara, P. N., DeVere White, R. W., Gao, A. C., & Evans, C. P. (2014) · Oncogene · doi:10.1038/onc.2014.25 · Cited by 212
Castration-recurrent prostate cancer is not androgen-independent.
Mohler, J. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_21 · Cited by 106 · cited 1×
“In fact, despite the dramatic decrease of serum T induced by ADT, CRPC remains driven by AR signaling, being able to overexpress androgen dependent genes [13].”
Cited by
Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., Massard, C., Matsubara, N., Alekseev, B., Parnis, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00580-8 · Cited by 335
Dorff, T., Horvath, L. G., Autio, K., Bernard-Tessier, A., Rettig, M. B., Machiels, J.-P., Bilen, M. A., Lolkema, M. P., Adra, N., Rottey, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2978 · Cited by 76
Metadata
- Authors
- Buttigliero, C., Tucci, M., Bertaglia, V., Vignani, F., Bironzo, P., Di Maio, M., & Scagliotti, G. V.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 41
- Issue
- 10
- Pages
- 884-892
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W1634543743
- Cited by
- 193
- References
- 16
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.